The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody
暂无分享,去创建一个
[1] P. Woo,et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. , 2005, Arthritis and rheumatism.
[2] T. Nomura,et al. Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. , 2004, The Journal of clinical investigation.
[3] N. Miyasaka,et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. , 2004, Arthritis and rheumatism.
[4] T. Hibi,et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. , 2004, Gastroenterology.
[5] K. Hagihara,et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. , 2003, Arthritis and rheumatism.
[6] K. Yoshizaki,et al. Influences of anti-mouse interleukin-6 receptor antibody on immune responses in mice. , 2002, Immunology letters.
[7] K. Yoshizaki,et al. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. , 2002, Arthritis and rheumatism.
[8] S. Sawhney,et al. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders , 2001, Archives of disease in childhood.
[9] M. Neurath,et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo , 2000, Nature Medicine.
[10] T. Kishimoto,et al. IL-6 Is Required for the Development of Th1 Cell-Mediated Murine Colitis1 , 2000, The Journal of Immunology.
[11] S. Nakae,et al. Development of Chronic Inflammatory Arthropathy Resembling Rheumatoid Arthritis in Interleukin 1 Receptor Antagonist–Deficient Mice , 2000, The Journal of experimental medicine.
[12] T. Kishimoto,et al. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. , 1998, Arthritis and rheumatism.
[13] M. Suarez‐Almazor,et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. , 1998, The Journal of rheumatology.
[14] Y. Ohsugi,et al. IL‐6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice , 1998, Clinical and experimental immunology.
[15] G. Kollias,et al. Interleukin 6 Is Required for the Development of Collagen-induced Arthritis , 1998, The Journal of experimental medicine.
[16] A. Martini,et al. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? , 1998, The Journal of rheumatology.
[17] Y. Kanai,et al. Autoimmunity induction by human T cell leukemia virus type 1 in transgenic mice that develop chronic inflammatory arthropathy resembling rheumatoid arthritis in humans. , 1995, Journal of immunology.
[18] M. Tsuchiya,et al. Establishment of a novel myeloma cell line KPMM2 carrying t(3;14)(q21;q32), which proliferates specifically in response to interleukin-6 through an autocrine mechanism. , 1995, Leukemia.
[19] J Saldanha,et al. Humanization of a mouse anti-human interleukin-6 receptor antibody comparing two methods for selecting human framework regions. , 1994, Molecular immunology.
[20] N. Udagawa,et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[21] I. Takata,et al. Enhanced expression of interleukin 6 in rat and murine arthritis models. , 1993, International journal of immunopharmacology.
[22] J. Hyams,et al. Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. , 1993, Gastroenterology.
[23] I. Takata,et al. Effect of a novel anti-rheumatic drug, TA-383, on type II collagen-induced arthritis--suppressive effect of TA-383 on interleukin 6 production. , 1993, International journal of immunopharmacology.
[24] R. Madhok,et al. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. , 1993, Annals of the rheumatic diseases.
[25] M. Alarcón‐Riquelme,et al. Age-dependent responsiveness to interleukin-6 in B lymphocytes from a systemic lupus erythematosus-prone (NZB x NZW)F1 hybrid. , 1992, Clinical immunology and immunopathology.
[26] J. Schölmerich,et al. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. , 1992, Gastroenterology.
[27] D. Kioussis,et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. , 1991, The EMBO journal.
[28] C. Gordon,et al. Urinary IL‐6: a marker for mesangial proliferative glomerulonephritis? , 1991, Clinical and experimental immunology.
[29] M. Linker-Israeli,et al. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. , 1991, Journal of immunology.
[30] K. Tanikawa,et al. Significance of interleukin-6 in patients with inflammatory bowel disease , 1991, Gastroenterologia Japonica.
[31] A. Fontana,et al. Interleukin-6 is elevated in plasma in multiple sclerosis , 1991, Journal of Neuroimmunology.
[32] L. Neckers,et al. Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. , 1991, Blood.
[33] T. Hirano,et al. Molecular cloning and expression of an IL-6 signal transducer, gp130 , 1990, Cell.
[34] Y. Koishihara,et al. Immunologic abnormality in NZB/W Fl mice. Thymus‐independent expansion of B cells responding to interleukin‐6 , 1990, Clinical and experimental immunology.
[35] S. Hirohata,et al. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. , 1990, Arthritis and rheumatism.
[36] J V Castell,et al. Interleukin-6 and the acute phase response. , 1990, The Biochemical journal.
[37] H. Hatanaka,et al. Interleukin-6 as a neurotrophic factor for promoting the survival of cultured basal forebrain cholinergic neurons from postnatal rats , 1989, Neuroscience Letters.
[38] T. Hirano,et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130 , 1989, Cell.
[39] S. Burstein,et al. Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[40] D. P. Murphy,et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[41] J. Lotem,et al. The Molecular Regulators of Macrophage and Granulocyte Development , 1989, Annals of the New York Academy of Sciences.
[42] P. Guerne,et al. Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. , 1989, The Journal of clinical investigation.
[43] T. Hirano,et al. Excessive production of interleukin 6/B cell stimulatory factor‐2 in rheumatoid arthritis , 1988, European journal of immunology.
[44] H. Imura,et al. Interleukin-6 stimulates the secretion of adrenocorticotropic hormone in conscious, freely-moving rats. , 1988, Biochemical and biophysical research communications.
[45] T. Taniguchi,et al. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. , 1988, Science.
[46] T. Hirano,et al. Induction of neuronal differentiation in PC12 cells by B-cell stimulatory factor 2/interleukin 6 , 1988, Molecular and cellular biology.
[47] F. Houssiau,et al. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. , 1988, Arthritis and rheumatism.
[48] T. Hirano,et al. B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes , 1988, The Journal of experimental medicine.
[49] A Muraguchi,et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells , 1988, The Journal of experimental medicine.
[50] J. Ihle,et al. Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[51] R. Simpson,et al. Purification and characterization of human fibroblast-derived hybridoma growth factor identical to T-cell-derived B-cell stimulatory factor-2 (interleukin-6). , 1987, European journal of biochemistry.
[52] P. Lansdorp,et al. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[53] T. Taniguchi,et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin , 1986, Nature.
[54] J H Korn,et al. Structure and expression of cDNA and genes for human interferon‐beta‐2, a distinct species inducible by growth‐stimulatory cytokines. , 1986, The EMBO journal.
[55] G. Volckaert,et al. Structural analysis of the sequence coding for an inducible 26-kDa protein in human fibroblasts. , 1986, European journal of biochemistry.
[56] P. Emery,et al. Efficacy of IL-6 receptor antagonist Mra in rheumatoid arthritis patients with an incomplete response to methotrexate (CHARISMA). , 2003 .